Special Issue "Pathology of Breast Cancer"
Deadline for manuscript submissions: closed (10 October 2023) | Viewed by 3256
2. Department of Pathology, University Hospital of Patras, 26504 Patras, Greece
Interests: tumor pathology; breast pathology; hematopathology; liver pathology; tumor biomarkers; cancer biology
Breast carcinoma (BC) is the most common cancer and the second leading cause of cancer death in women, accounting for 12% of all new annual cancer cases worldwide. In the past two decades, advancements in molecular techniques have contributed to an improved understanding of BC biology, significant developments in the classification of breast cancer and enrichment with new molecular subtypes that have altered the daily practice of pathology. The emerging molecular classifications of BC bring novel perspectives to the assessment of individual cases and opportunities for improved management in the era of precision medicine.
Recently, molecular studies have further illuminated the heterogeneity of BC subtypes, from the better-known biological subsets of triple-negative breast carcinoma (TNBC) and HER2-positive BC to the less published luminal BCs. Teasing out the distinct subtypes allows for novel targeted therapies to be developed and implemented under the umbrella of personalized medicine.
The prognostic and predictive utility of histopathologic parameters associated with the tumor microenvironment (TME), such as tumor-infiltrating lymphocytes (TILs), are also being elucidated, and new protocols have been devised for the pathologic assessment of BC specimens that have undergone neoadjuvant therapy.
In this Special Issue, we are interested in papers that focus on the current diagnostic approaches and developments in the pathology of BC, the surgical advancements in the management of the breast and the axilla and novelties in oncological and radiotherapeutic management that impact our practices. Original articles and systematic reviews are equally welcome.
Prof. Dr. Vasiliki Zolota
Prof. Dr. Helen Kourea
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- breast cancer biomarkers
- triple negative breast cancer
- breast cancer carcinogenesis
- breast cancer biology